» Articles » PMID: 36055826

Utility of Synthetic MRI in Predicting Pathological Complete Response of Various Breast Cancer Subtypes Prior to Neoadjuvant Chemotherapy

Overview
Journal Clin Radiol
Specialty Radiology
Date 2022 Sep 2
PMID 36055826
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: To evaluate the usefulness of synthetic magnetic resonance imaging (MRI) performed before the initiation of neoadjuvant chemotherapy (NAC) in predicting whether breast cancers can achieve a pathological complete response (pCR) after the completion of NAC.

Materials And Methods: This retrospective study investigated 37 consecutive patients with 39 breast cancers (pCR: 14, and non-pCR: 25) who underwent dynamic contrast-enhanced (DCE)-MRI and synthetic MRI before the initiation of NAC. Using synthetic MRI images, quantitative values (T1 and T2 relaxation times, proton density [PD] and their standard deviations [SD]) were obtained in breast lesions, before (Pre-T1, Pre-T2, Pre-PD, SD of Pre-T1, SD of Pre-T2, SD of Pre-PD) and after (Gd-T1, Gd-T2, Gd-PD, SD of Gd-T1, SD of Gd-T2, SD of Gd-PD) contrast agent injection. The aforementioned quantitative values and several morphological features that were identified on DCE-MRI were compared between pCR and non-pCR.

Results: Multivariate analyses revealed that the SD of Pre-T2 (p=0.038) was significant and was an independent predictor of pCR, with an area under the receiver operating characteristics curve of 0.829. The sensitivity, specificity, and accuracy of the SD of Pre-T2 with an optimal cut-off value of 11.5 were 71.4%, 80%, and 76.3%, respectively.

Conclusions: The SD of Pre-T2 obtained from synthetic MRI was used successfully to predict those breast cancers that would achieve a pCR after the completion of NAC; however, these results are preliminary and need to be verified by further studies.

Citing Articles

Synthetic MRI plus FSE-PROPELLER DWI for differentiating malignant from benign head and neck tumors: a preliminary study.

Wen B, Zhang Z, Zhu J, Liu L, Liu Z, Ma X Front Oncol. 2023; 13:1225420.

PMID: 37829331 PMC: 10565487. DOI: 10.3389/fonc.2023.1225420.


Correlation between synthetic MRI relaxometry and apparent diffusion coefficient in breast cancer subtypes with different neoadjuvant therapy response.

Jiang W, Du S, Gao S, Xie L, Xie Z, Wang M Insights Imaging. 2023; 14(1):162.

PMID: 37775610 PMC: 10541382. DOI: 10.1186/s13244-023-01492-9.


A Radiomics Model Based on Synthetic MRI Acquisition for Predicting Neoadjuvant Systemic Treatment Response in Triple-Negative Breast Cancer.

Hwang K, Elshafeey N, Kotrotsou A, Chen H, Son J, Boge M Radiol Imaging Cancer. 2023; 5(4):e230009.

PMID: 37505106 PMC: 10413296. DOI: 10.1148/rycan.230009.


Using Synthetic MRI and Radiomics to Predict Treatment Response in Triple-Negative Breast Cancer.

Houser M, Rapelyea J Radiol Imaging Cancer. 2023; 5(4):e230095.

PMID: 37505105 PMC: 10413287. DOI: 10.1148/rycan.230095.


Pretreatment synthetic magnetic resonance imaging predicts disease progression in nonmetastatic nasopharyngeal carcinoma after intensity modulation radiation therapy.

Yang F, Wei H, Li X, Yu X, Zhao Y, Li L Insights Imaging. 2023; 14(1):59.

PMID: 37016104 PMC: 10073373. DOI: 10.1186/s13244-023-01411-y.